Skip to main content

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.

Leukemia

Authors: Elias K Mai, Thomas Hielscher, Uta Bertsch, Hans J Salwender, Sonja Zweegman, Marc S Raab, Markus Munder, Lucia Pantani, Katia Mancuso, Peter Brossart, Meral Beksac, Igor W Blau, Jan Dürig, Britta Besemer, Roland Fenk, Peter Reimer, Bronno van der Holt, Mathias Hänel, Ivana von Metzler, Ullrich Graeven, Carsten Müller-Tidow, Mario Boccadoro, Christof Scheid, Meletios A Dimopoulos, Jens Hillengass, Katja C Weisel, Michele Cavo, Pieter Sonneveld, Hartmut Goldschmidt

Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection/death were identified: low platelet count (<150/nL), ISS III, higher WHO performance status (>1), and age (>60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; ≥2 points) risk. The risk for severe infection/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (p < 0.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.

© 2023. The Author(s).

PMID: 38062124

Participating cluster members